TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21434963

Group type: EXPERIMENTAL
Intervention: Resilient appliance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hard, palatal, non-occluding appliance (Control)
Number of subjects: 80
Study: 19419343

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 143

Group type: COMPARATOR
Intervention: Azithromycin 500 mg once daily on day 1 and 250 mg once daily on days 2 through 5
Number of subjects: 143
Study: 17298647

Group type: EXPERIMENTAL
Intervention: Attentional re-training (AR; modified visual-probe task)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control condition (standard visual-probe task)
Number of subjects: 106
Study: 14759955

Group type: EXPERIMENTAL
Intervention: Web intervention group with continuous access to a bioterrorism educational Web site and weekly exposure to case scenarios.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 63
Study: 11731398

Group type: EXPERIMENTAL
Intervention: Information pack and supplementary phone call
Number of subjects: 325

Group type: COMPARATOR
Intervention: Information pack only
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Information pack and phone call
Number of subjects: 325
Study: 9130735

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zoladex with MPA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 8195463

Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) coadministered with fluoxetine (20 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) coadministered with sertraline (50 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) after sertraline discontinuation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg/day) after fluoxetine discontinuation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluoxetine/norfluoxetine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sertraline/desmethylsertraline
Number of subjects: 18
Study: 3315118

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing factor (CRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing factor (CRF) in rats
Number of subjects: 0
Study: 30390870

Group type: EXPERIMENTAL
Intervention: Milk-honey mixture (twice a day for three days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 68
Study: 27166794

Group type: EXPERIMENTAL
Intervention: 0.5 mg of folic acid daily (Group 1)
Number of subjects: 460

Group type: COMPARATOR
Intervention: 5 mg of folic acid daily (Group 2)
Number of subjects: 460
Study: 25594129

Group type: EXPERIMENTAL
Intervention: Combination blue light therapy (n = 26)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (n = 15)
Number of subjects: 41
Study: 23870722

Group type: EXPERIMENTAL
Intervention: 1.2 g/day n-3 PUFAs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21691804

Group type: EXPERIMENTAL
Intervention: TNF‐α blockers (Infliximab and Adalimumab)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: TNF‐α blockers
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Control (Placebo or other drugs)
Number of subjects: 1226
Study: 18378871

Group type: EXPERIMENTAL
Intervention: Anxiety symptoms assessment using the State Trait Anxiety Inventory at baseline, 6, and 18 months
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Multinomial logistic regression analyses
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Absence of angina and major depression, not using diuretics
Number of subjects: 638
Study: 16113850

Group type: EXPERIMENTAL
Intervention: Symptomatic drugs (dipirone or diazepan)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anti-hypertensive drug (captopril)
Number of subjects: 100
Study: 12944062

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Imatinib (cytogenetic responders)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Imatinib (non-responders)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional treatment (historical controls)
Number of subjects: 143
Study: 10799197

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (25 patients)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (26 patients)
Number of subjects: 51
Study: 8815681

Group type: EXPERIMENTAL
Intervention: Polyclonal immunoglobulin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal anti‐CMV antibodies (MSL‐109)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of CMV‐specific CD8 cells
Number of subjects: 0
Study: 1612492

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (5 mg four times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6430142

Group type: EXPERIMENTAL
Intervention: Oral sodium citrate (1.3 meq/kg body weight daily for 8 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo solution (for 8 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral sodium citrate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral sodium citrate and acetate dialysate
Number of subjects: 12
Study: 31753261

Group type: EXPERIMENTAL
Intervention: Supplemental Nutrition Assistance Program participants
Number of subjects: 950

Group type: COMPARATOR
Intervention: Nonparticipants
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: SNAP participants
Number of subjects: 950

Group type: COMPARATOR
Intervention: Difference-in-difference estimators comparing SNAP participants with nonparticipants
Number of subjects: 950
Study: 28744993

Group type: EXPERIMENTAL
Intervention: Machined implants in smokers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall (smokers and non-smokers)
Number of subjects: 32
Study: 26065445

Group type: EXPERIMENTAL
Intervention: Metronidazole 1,000 mg every 24 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg (single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole 1,000 mg (single oral dose)
Number of subjects: 0
Study: 24050419

Group type: EXPERIMENTAL
Intervention: Community-based diet, physical activity, and stress reduction intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 159
Study: 21474700

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hyperventilation (HV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT)
Number of subjects: 29
Study: 20037644

Group type: EXPERIMENTAL
Intervention: FP9-TRAP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA-TRAP vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rabies vaccination (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FFM ME-TRAP vaccine
Number of subjects: 0
Study: 16773437

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175, 210, and 250 mg/m² over 3 h every 3 weeks)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: IL-6 expression
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: PGP expression
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of IL-6 and PGP
Number of subjects: 469
Study: 12842680

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anesthesia with i.v. cannula
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anesthesia without i.v. cannula
Number of subjects: 119

Group type: COMPARATOR
Intervention: Topical anesthesia of proparacaine 0.5% without i.v. cannula
Number of subjects: 119
Study: 11085807

Group type: EXPERIMENTAL
Intervention: 10,640 IU 25-HCC per week + 1 g calcium per day
Number of subjects: 58

Group type: COMPARATOR
Intervention: 1 g calcium per day
Number of subjects: 58
Study: 8775098

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study: 1615177

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone diproprionate (1500 micrograms day‐1)
Number of subjects: 20
Study: 6377865

Group type: EXPERIMENTAL
Intervention: Propranolol b.i.d. (80, 160, 320 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Propranolol q.i.d. (80, 160, 320 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Propranolol q.d. (80, 160, 320 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Propranolol b.i.d.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Propranolol q.i.d.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Propranolol q.d.
Number of subjects: 78
Study: 30360658

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (250 μg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate
Number of subjects: 53
Study: 30027756

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 10 weeks)
Number of subjects: 0
Study: 27687441

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.75 μg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 μg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 μg/kg
Number of subjects: 60
Study: 24488793

Group type: EXPERIMENTAL
Intervention: Preoperative cryotherapy (30 to 90 minutes)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standardized postoperative treatment plan alone (no preoperative cryotherapy)
Number of subjects: 53
Study: 22285579

Group type: EXPERIMENTAL
Intervention: Patients with ISA (n = 37, 39 lesions)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Patients without ISA (n = 157, 182 lesions)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Patients with ISA
Number of subjects: 194

Group type: COMPARATOR
Intervention: Patients without ISA
Number of subjects: 194
Study: 20070143

Group type: EXPERIMENTAL
Intervention: Famciclovir 1000 mg twice-daily
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 17663608

Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 0
Study: 16109464

Group type: COMPARATOR
Intervention: Radiation Therapy (RT) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RT plus total androgen suppression (RTHormones)
Number of subjects: 100
Study: 12110494

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (1000 mg/m2) on day 1 preceding cisplatin infusion, 30 mg/m2/24 h cisplatin intravenous bolus days 1-4, and 1000 mg/m2/24 h 5-FU in a 4-h infusion on days 1-4.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cisplatin (30 mg/m2/24 h) and 5-FU in the same dosage and schedule as in arm A.
Number of subjects: 170
Study: 10194886

Group type: EXPERIMENTAL
Intervention: Interactive videodisc instruction (IVDI) with cooperative learning strategies
Number of subjects: 0
Study: 8524975

Group type: EXPERIMENTAL
Intervention: m‐chlorophenylpiperazine (m‐CPP, 0.08 mg/kg IV) with scopolamine (0.4 mg IV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg IV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ondansetron (0.15 mg/kg IV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg IV) + ondansetron (0.15 mg/kg IV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 2405105

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus Leucovorin (LV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus Placebo
Number of subjects: 61
Study: 6101959

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.25 mg
Number of subjects: 6
Study: 31397645

Group type: EXPERIMENTAL
Intervention: Greater perceived burden
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Greater thwarted belonging
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mobility, cognition, and social participation
Number of subjects: 62
Study: 30772853

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for pressure ulcers
Number of subjects: 0
Study: 28863395

Group type: EXPERIMENTAL
Intervention: aPDT Group (n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: MTZ+AMX Group (n=17)
Number of subjects: 34
Study: 25587020

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 23502660

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Phenytoin (after crossover)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (after crossover)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (maximum dose)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Phenytoin (maximum dose)
Number of subjects: 109
Study: 21539759

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (30 mg/1 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nalbuphine (10 mg/1 ml)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 150
Study: 19438689

Group type: EXPERIMENTAL
Intervention: Ablative fractional laser with high energy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of ablative fractional laser resurfacing and nonablative laser resurfacing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ablative fractional laser with low energy plus nonablative resurfacing laser
Number of subjects: 20
Study: 17084250

Group type: EXPERIMENTAL
Intervention: Torcetrapib 10, 30, 60, or 90 mg/day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Torcetrapib plus atorvastatin
Number of subjects: 174
Study: 11813226

Group type: EXPERIMENTAL
Intervention: Different recruitment strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intuitive methods of describing clustering
Number of subjects: 0
Study: 10088980

Group type: EXPERIMENTAL
Intervention: Prophylactic counseling (intervention group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monitoring (control group)
Number of subjects: 40
Study: 7569283

Group type: EXPERIMENTAL
Intervention: Mesoglycan 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mesoglycan 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2188847

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7002481

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steroid injection with placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steroid injection with active tolmetin sodium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiotherapy (ultrasound)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo physiotherapy with placebo tolmetin sodium
Number of subjects: 60
Study: 31559422

Group type: EXPERIMENTAL
Intervention: Presence of Rhodnius prolixus in rural dwellings
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proportions of males, females, and nymphs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Density, crowding, and colonization indices
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Molecular analysis for T. cruzi DNA
Number of subjects: 30
Study: 30012273

Group type: EXPERIMENTAL
Intervention: Peek school eye health system (smartphone-based sight test and referral system)
Number of subjects: 20563

Group type: COMPARATOR
Intervention: Standard care (Snellen's Tumbling‐E card and written referral)
Number of subjects: 20563

Group type: EXPERIMENTAL
Intervention: Peek school eye health system
Number of subjects: 20563

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20563
Study: 28433091

Group type: EXPERIMENTAL
Intervention: Cool Little Kids Online parenting program
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control group (24-week waitlist)
Number of subjects: 433
Study: 26329674

Group type: EXPERIMENTAL
Intervention: Intermittent high-volume hemofiltration (IHVHF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (SRD)
Number of subjects: 51
Study: 24284101

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA), 1.0 g, orally administered
Number of subjects: 66
Study: 21034293

Group type: EXPERIMENTAL
Intervention: Acute stress (Trier Social Stress Test)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 32
Study: 18714218

Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (SUPP) - 201 mg of caffeine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLAC) - microcrystalline cellulose
Number of subjects: 31
Study: 16353199

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg 3 times daily) plus vitamin D(3) 400 IU
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D
Number of subjects: 19
Study: 14723480

Group type: EXPERIMENTAL
Intervention: Concurrent smoking cessation treatment offered during intensive rehabilitation for alcohol dependence.
Number of subjects: 499

Group type: COMPARATOR
Intervention: Smoking cessation treatment offered six months following intensive rehabilitation for alcohol dependence.
Number of subjects: 499
Study: 10200915

Group type: EXPERIMENTAL
Intervention: 3-week in-patient rehabilitation course
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exercise recommendations)
Number of subjects: 60
Study: 7773794

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl-starch/7.5% NaCl (HHT-HES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10% hydroxyethyl-starch/.9% NaCl (HES)
Number of subjects: 40
Study: 2100976

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 424688

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 565
Study: 31097283

Group type: EXPERIMENTAL
Intervention: True electroacupuncture group (TEAG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham electroacupuncture group (SEAG)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: True electroacupuncture plus rehabilitation
Number of subjects: 21
Study: 30155678

Group type: EXPERIMENTAL
Intervention: Huangqi Decoction Granules (HQDG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 70
Study: 28652066

Group type: EXPERIMENTAL
Intervention: Shoulder girdle stretching and strengthening with additional scapular stabilization exercises based on a kinetic chain approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Shoulder girdle stretching and strengthening exercises only
Number of subjects: 30
Study: 27144943

Group type: EXPERIMENTAL
Intervention: Postoperative transthoracic echocardiography (TTE) findings
Number of subjects: 147
Study: 24680572

Group type: EXPERIMENTAL
Intervention: Intraperitoneal polypropylene omega-3 mesh (group B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Nonabsorbable sutures (group A)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 22277092

Group type: EXPERIMENTAL
Intervention: NAC with epirubicin or paclitaxel monotherapy
Number of subjects: 89
Study: 19411450

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (fusion group, n = 37)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Without posterolateral fusion (nonfusion group, n = 36)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (fusion group)
Number of subjects: 73
Study: 17204680

Group type: EXPERIMENTAL
Intervention: Lokomat robotic training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 30
Study: 16343082

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BCG vaccination at 2 months (group II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BCG vaccination (both groups)
Number of subjects: 40
Study: 11991445

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 225

Group type: COMPARATOR
Intervention: E2/NETA (estradiol 2 mg plus norethindrone acetate 1 mg)
Number of subjects: 225
Study: 9806503

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy (ChT) followed by standard radiation therapy (RT) (60 Gy in 6 weeks)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Combined sequential and concurrent ChT and standard RT (60 Gy in 6 weeks)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Concurrent ChT and hyperfractionated RT (69.6 Gy in 6 weeks)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Sequential ChT followed by standard RT (60 Gy in 6 weeks)
Number of subjects: 461
Study: 8536530

Group type: EXPERIMENTAL
Intervention: Standard ramp distension with 4 mm Hg pressure step increments of 20 sec duration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Slow ramp distension with 2 mm Hg pressure increments of 40 sec duration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Random distension using a pressure ramp consisting of 2 mm Hg increments of 40 sec duration with randomly interposed pressure steps 50% below the preceding pressure step
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rapid random distension with 4 mm Hg pressure increments of 10 sec duration with randomly interposed pressure steps 50% below the preceding pressure step
Number of subjects: 7
Study: 29547448

Group type: EXPERIMENTAL
Intervention: Robotic training with pelvis assistance force
Number of subjects: 16

Group type: COMPARATOR
Intervention: Treadmill-only training
Number of subjects: 16